Tags

Type your tag names separated by a space and hit enter

FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors on Non-Small Cell Lung Cancer Cells (NSCLC).
J Biophotonics 2019; :e201960012JB

Abstract

ATP-analogue inhibitors, Gefitinib (Iressa) and Erlotinib (Tarceva), had been approved for advanced and metastatic NSCLC against tyrosine kinase domain of EGFR. Many techniques have been developed to better understand the drug mechanism which is multistep, time-consuming, and expensive. Herein, we performed Fourier transform infrared microscopy (FTIR) for evaluating the biochemical change on NSCLC (A549) cells after treatment. At levels that produced equivalent effects, Gefitinib dramatically induced cell apoptosis via impaired mitochondrial transmembrane potential. Whereas, Erlotinib had a slight effect on A549. Principal component analysis (PCA) was performed to distinguish the effect of EGFR inhibitors on A549. FTIR spectra regions were divided into three regions; lipids (3000-2800 cm-1), proteins (1700-1500 cm-1), and carbohydrates and nuclei acids (1200-1000 cm-1). Biochemical changes can be evaluated by these spectral regions. This work may be a novel concept for utilizing FTIR spectroscopy for high-throughput discriminative effects of a drug or compound and its derivatives on cells. This article is protected by copyright. All rights reserved.

Authors+Show Affiliations

Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, Thailand.Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, Thailand.Synchrotron Light Research Institute (Public Organization), Nakhon Ratchasrima, Thailand.Synchrotron Light Research Institute (Public Organization), Nakhon Ratchasrima, Thailand.Department of Biochemistry, Faculty of Science, Kasetsart University, Bangkok, Thailand. Center for Advanced Studies in Nanotechnology for Chemical, Food and Agricultural Industries, KU Institute for Advanced Studies, Kasetsart University, Bangkok, Thailand.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

31595681

Citation

Tabtimmai, Lueacha, et al. "FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors On Non-Small Cell Lung Cancer Cells (NSCLC)." Journal of Biophotonics, 2019, pp. e201960012.
Tabtimmai L, Srisook P, Kuaprasert B, et al. FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors on Non-Small Cell Lung Cancer Cells (NSCLC). J Biophotonics. 2019.
Tabtimmai, L., Srisook, P., Kuaprasert, B., Thumanu, K., & Choowongkomon, K. (2019). FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors on Non-Small Cell Lung Cancer Cells (NSCLC). Journal of Biophotonics, pp. e201960012. doi:10.1002/jbio.201960012.
Tabtimmai L, et al. FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors On Non-Small Cell Lung Cancer Cells (NSCLC). J Biophotonics. 2019 Oct 8;e201960012. PubMed PMID: 31595681.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - FTIR Spectra Signatures Reveal Different Cellular Effects of EGFR Inhibitors on Non-Small Cell Lung Cancer Cells (NSCLC). AU - Tabtimmai,Lueacha, AU - Srisook,Pimonwan, AU - Kuaprasert,Buabarn, AU - Thumanu,Kanjana, AU - Choowongkomon,Kiattawee, Y1 - 2019/10/08/ PY - 2019/06/25/received PY - 2019/08/25/revised PY - 2019/10/02/accepted PY - 2019/10/10/entrez PY - 2019/10/9/pubmed PY - 2019/10/9/medline KW - Fourier transform infrared microscopy (FTIR) KW - biochemical change KW - epidermal growth factor receptor (EGFR) KW - non-small cell lung cancer (NSCLC) KW - tyrosine kinase inhibitor (TKI) SP - e201960012 EP - e201960012 JF - Journal of biophotonics JO - J Biophotonics N2 - ATP-analogue inhibitors, Gefitinib (Iressa) and Erlotinib (Tarceva), had been approved for advanced and metastatic NSCLC against tyrosine kinase domain of EGFR. Many techniques have been developed to better understand the drug mechanism which is multistep, time-consuming, and expensive. Herein, we performed Fourier transform infrared microscopy (FTIR) for evaluating the biochemical change on NSCLC (A549) cells after treatment. At levels that produced equivalent effects, Gefitinib dramatically induced cell apoptosis via impaired mitochondrial transmembrane potential. Whereas, Erlotinib had a slight effect on A549. Principal component analysis (PCA) was performed to distinguish the effect of EGFR inhibitors on A549. FTIR spectra regions were divided into three regions; lipids (3000-2800 cm-1), proteins (1700-1500 cm-1), and carbohydrates and nuclei acids (1200-1000 cm-1). Biochemical changes can be evaluated by these spectral regions. This work may be a novel concept for utilizing FTIR spectroscopy for high-throughput discriminative effects of a drug or compound and its derivatives on cells. This article is protected by copyright. All rights reserved. SN - 1864-0648 UR - https://www.unboundmedicine.com/medline/citation/31595681/FTIR_Spectra_Signatures_Reveal_Different_Cellular_Effects_of_EGFR_Inhibitors_on_Non-Small_Cell_Lung_Cancer_Cells_(NSCLC) L2 - https://doi.org/10.1002/jbio.201960012 DB - PRIME DP - Unbound Medicine ER -